Topic: cPass SARS-CoV-2 Neutralization Antibodies Detection Kit: A powerful tool for the detection of functional neutralizing antibodies
Speaker:
Title: Field Application Scientist, GenScript
Abstract:
The coronavirus disease 2019 (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This outbreak was firstly reported in Wuhan, China. On 11th March 2020, the World Health Organization (WHO) has recognized the outbreak as a pandemic. It is reported that the SARS-CoV-2 is affecting 197 countries and territories around the world. Worryingly, the number is still increasing dramatically. Not only that novel pandemic posing a great threat to global public health, it has led to global economic slowdown and socioeconomic disruption.
An accurate, rapid and simple detection method plays an important role to quickly identify large number of infected patients and asymptomatic carriers to prevent virus transmission and assure timely treatment of patients. Thanks to the advancement of the technologies, numerous detection assays based on the nucleic acids and human sera are available. Moreover, other clinical diagnostic tools such as Chest CT imaging can also be used to improve and allow for the confirmation of infection. On the other hand, scientists have been racing to develop the vaccines and antiviral drugs against the virus. In addition, numerous programs and fund have been rolled out to support the development.
Dr. Edward will be presenting a review of the nucleic acid- and sera-based detection assays for COVID-19 and the current trend of vaccine and drug development. In addition, he will be presenting how GenScript could have helped in accelerating the research and development.
Key points to be covered:
- Brief introduction of COVID-19
- Review of the currently available detection methods for SARS-CoV-2
- Discussion of the current trend of vaccine and drug development
No one knows what’s coming next post COVID-19, but everyone’s getting ready for it as fast as they can. The urge to anticipate the future, whatever it brings, is understandable. COVID-19 has offered a unique opportunity for India to re-charge its "Make in India" mantra. It is playing a catalytic role by enabling India's best innovative minds to develop solutions towards easing the healthcare community pressure and help save lives. Perhaps it is time for India to emerge as a leader in the life sciences sector and be future-ready.
Early Phase Clinical Trials: Why taking the whole-of-health perspective is critical
Hear first-hand about the importance of planning with the end goal in mind while engaging and investing in subject matter expertise as early as possible in program drug development planning
Hear from Professor Guy Ludbrook, Director of PARC Clinical Research, at the Royal Adelaide Hospital and Dr. Gabriel Kremmidiotis, Chief Scientific Officer at Avance Clinical, on how to navigate drug development, strategy and regulatory policy in planning early phase trials
Regulatory reliance and desk-top inspections – The new normal?
Will your next regulatory inspection be a desk-top one? Hear from former FDA and MHRA staff how Drug Regulators are doing this and how you need to be ready for your next inspection.
Live-Cell Analysis in 2020: Advancing Technology to Meet Researchers' Needs
Technological advances are driving rapid progress in disease areas such as oncology, immuno-oncology and neuroscience, revealing new treatment possibilities. Scientists are now able to interrogate cellular biology and cell-to-cell interactions in previously unachievable ways, gaining deeper insight, faster, and advancing the development of innovative strategies for targeting cancer.
Notable developments in live-cell assays and in vitro translational models have enabled real-time studies of cancer cells, using systems such as Incucyte®.
Learn more on latest Incucyte® Live-Cell Analysis Systems technology.
